Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110250082 | 11025008 | 2 | F | 20160711 | 20150414 | 20160718 | EXP | SI-ASTELLAS-2015US011728 | ASTELLAS | ZWITTER M, RAJER M, STANIC K, VRANKAR M, DOMA A, CUDERMAN A ET AL. INTERCALATED CHEMOTHERAPY AND ERLOTINIB FOR NON-SMALL CELL LUNG CANCER (NSCLC) WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS. CANCER BIOLOGY AND THERAPY. 2016;1-7 | 0.00 | Y | 0.00000 | 20160718 | COUNTRY NOT SPECIFIED | SI |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110250082 | 11025008 | 1 | PS | Erlotinib | ERLOTINIB | 1 | Oral | 150 MG, FROM DAY 5 TO 15 EVERY 3 WEEKS CYCLE | U | 21743 | 150 | MG | TABLET | ||||||
| 110250082 | 11025008 | 2 | SS | Erlotinib | ERLOTINIB | 1 | Oral | UNINTERRUPTED MAINTENANCE | 21743 | TABLET | |||||||||
| 110250082 | 11025008 | 3 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | DAYS 1 AND 4, 1250 MG/M2, EVERY 3 WEEKS | U | 0 | 1250 | MG/M**2 | FORMULATION UNKNOWN | Q3W | |||||
| 110250082 | 11025008 | 4 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | ON DAY 2, 75 MG/M2, EVERY 3 WEEKS | U | 0 | 75 | MG/M**2 | FORMULATION UNKNOWN | Q3W |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 110250082 | 11025008 | 1 | Non-small cell lung cancer |
| 110250082 | 11025008 | 3 | Non-small cell lung cancer |
| 110250082 | 11025008 | 4 | Non-small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 110250082 | 11025008 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 110250082 | 11025008 | Anaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |